Advertisement

Topics

Seattle Genetics Submits sBLA to FDA for Adcetris in Frontline Advanced Hodgkin Lymphoma

10:41 EDT 3 Nov 2017 | Speciality Pharma Journal

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 ECHELON-1 trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma. ADCETRIS is …

Original Article: Seattle Genetics Submits sBLA to FDA for Adcetris in Frontline Advanced Hodgkin Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics Submits sBLA to FDA for Adcetris in Frontline Advanced Hodgkin Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...